Psoriasis is a common inflammatory skin disease characterized by infiltration of inflammatory cells into the epidermis and altered keratinocyte differentiation. Psoriasis is currently thought of as a T-cell mediated 'Type-1' autoimmune disease. Gene expression changes in psoriasis lesions have been well documented, and strongly support an important role for tumor necrosis factor and interferon gamma signal pathways in its pathogenesis. The strongest genetic determinant of psoriasis identified to date lies within the class I region of the multiple histocompatibility locus antigen cluster, although its low penetrance implicates a requirement for other genetic risk factors. Multiple genome-wide linkage and an increasing number of association studies have been carried out, leading to multiple linkage peaks, and the identification of potential low risk variants. A number of these variants lie within genes encoding components of the immune system. However, the functional relationships between predisposing genetic variation is unclear, and presumably involves genetic susceptibility factors affecting both immune cell activation and keratinocyte differentiation. The interaction of environmental trigger factors with genetic effects is also not understood, but provide further evidence for the complex basis of this disease.
Introduction/historical perspective
Psoriasis is a common chronic inflammatory skin disease that affects 2-3% of the Caucasian population. It frequently develops in early adulthood in individuals between 15 and 30 years old, although individuals of all ages can be affected. The disease is characterized by thickened, scaly skin patches or psoriatic plaques, caused by abnormal keratinocyte proliferation and infiltration of inflammatory cells into the dermis and epidermis. Approximately 10-30% of patients with psoriasis also develop psoriasis arthritis. Once psoriasis appears, it is usually a life-long disease. Spontaneous disease improvement is uncommon and more severely affected individuals often have progressively increasing amounts of the skin surface affected.
One theory for the development of psoriasis is that T cells and dendritic cells (DCs) elaborate inflammatory cytokines and chemokines to create an environment in the skin that stimulates proliferation of resident keratinocytes and endothelial cells in genetically susceptible individuals, producing a pattern of growth recognized as psoriasis.
The view of psoriasis as a T-cell mediated 'autoimmune' or inflammatory disease has evolved most directly from clinical studies of disease response to a range of immune antagonists. However, this view of immune-mediated pathogenesis is also strongly supported from study of human skin xenografts in mice and by the identification of clonal populations of T cells within intact skin lesions.
Triggers
Psoriasis can be triggered by an array of factors that includes physical injury to the skin (the 'Koebner' response), administration of interferons (IFN) or other inflammation-inducing stimuli, rapid withdrawl of immunosuppressive drugs like corticosteroids and (systemic) infections with streptococcus or other bacteria. 1, 2 A recent report suggests that psoriasis can be induced by a chemical agonist that activates toll-like receptor 7. This may be via IFN-a secreted by dermal DCs. 3 Although these are diverse stimuli, all might be viewed as trigger factors that can activate cellular immunity. This could be through innate or acquired pathways and would serve as inducers of a chronically perpetuated immune response in the skin of predisposed individuals.
Regenerative keratinocyte differentiation in psoriasis Figure 1a illustrates some of the major differences between normal and involved psoriatic skin. The overall set of cellular and molecular changes in chronic psoriasis plaques is complex and large-scale genomic analyses have identified altered expression of 41300 gene products in involved skin of lesions compared to unaffected (non-lesional) skin of the same individuals. 4 Transcripts with the highest steady-state levels that are upregulated in involved skin are expressed by the keratinocyte. Some affect its innate immune system, including the upregulation of beta defensin. Expression levels of messenger RNAs (mRNAs) transcribed by T cells and DCs are at far lower levels owing to the overwhelming number of keratinocytes in lesions.
The transit from a basal keratinocyte to a desquamated cell takes 4-6 weeks in normal skin. In psoriasis this is dramatically shortened, occurring in only a few days. Many cellular products normally produced in the granular layer become expressed in upper spinous keratinocytes in the psoriatic lesion. These alterations are part of an accelerated differentiation also seen in regenerative maturation. 5 In normal skin this is a program triggered by wounding of the skin that rapidly initiates transcription of new genes in keratinocytes. This accelerates proliferation of basal keratinocytes, as well as the differentiation of spinous and granular keratinocytes and is associated with the induction of keratins 6 and 16 in suprabasal keratinocytes.
The physically expanded proliferative compartment is accompanied by suprabasal expression of insulin-like growth factor-1 receptors and b1-integrins. 6, 7 Corneocytes do form with corneodesmosomes and a cornified envelope, but neutral lipids are not secreted in a normal manner into the extracellular space from Odland bodies. 8, 9 The result of incomplete differentiation/parakeratosis is that the stratum corneum barrier is not formed correctly in psoriasis plaques. The consequences are a defective water/vapor barrier and the shedding of strateum corneum fragments in large sheets of scales/ flakes.
Intercellular cell adhesion molecule (ICAM)-1, CD40 and human leukocyte antigen dimensional reconstruction (HLA-DR) are expressed on the surface of some basal/suprabasal keratinocytes in psoriasis lesions. 10 ICAM-1 is a general ligand for b2-integrins expressed on T-cells, DCs and neutrophils and may enable intraepidermal trafficking of leukocytes. CD40 and HLA-DR molecules potentially interact with cognate receptors on T cells and could potentially deliver activation signals. Keratinocytes in psoriasis lesions also synthesize numerous proteins that can serve as chemotactic factors for the array of leukocytes found in lesional epidermis. 4 Activated keratinocytes mediate angiogenesis through increased synthesis of vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF) and other IL-1, IL-2, IL-2R, IL-2 inducible T-cell  kinase, TCRB, TNF, IFN-g, IL-17, VEGF, GM-CSF, LYN; dendritic cells in the epidermis express CD11c, DECTIN, IL-1b, IL-12, IL-23, TNF, IFN-a,  MDC/CCL22 , PARC/CCL18, Bonzo receptor ligand/CXCL16, MIP-3b/CCL19. Keratinocytes express IL-1b, IL-6, IL-8, Ltb, TNFIL-18, TGFa, amphiregulin, VEGF, PDGF, ECGF, Groa/MGSA, MCP-1/CCL2, MIP3a/CCL20, MIG/CXCL9, IP-10/CXCL10, I-TAC/CXCL11, RANTES/CCL5, ENA-78/CXCL5 and CTACK/CCL27. Each of these has an effect on other cell types in the skin, and on endothelial and stromal cells.
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Y Liu et al endothelial cell mitogens. [11] [12] [13] A unique link between regenerative hyperplasia and inflammation may be provided by synthesis of S100 proteins (A7, A8, A9, A12) that are encoded by the epidermal differentiation complex (EDC) genes. 14 In psoriasis lesions, there is tremendous growth of the most superficial capillaries. Highly elongated and tortuous vessels become very prominent in the elongated dermal papillae. Endothelial cells in these elongated vessels strongly express ICAM-1, the peripheral lymph node addressin, and a variety of other adhesion molecules that are normally restricted to vessels in lymph nodes or to secondary lymphoid tissues.
Keratinocytes in psoriasis plaques express some immune-related molecules that are not normally associated with wound-related regenerative hyperplasia. These immune-related molecules may be induced in keratinocytes following exposure to high concentrations of tumor necrosis factor (TNF) and g-IFN produced in psoriatic lesions, 15, 16 and may be specifically upregulated in genetically predisposed individuals.
Immune cells in psoriatic lesions
Immune cells that infiltrate into psoriatic skin are diagrammed in Figure 1b . In normal skin, a small number of T cells can be found in the dermis, but no T cells are located in the epidermis. Likewise, in normal skin, a relatively small number of myeloid (CD11c þ ) DCs are located in dermis, whereas Langerhans cells are found mainly in the epidermis. In psoriasis lesions, there are marked increases in the number of T cells and CD11c þ DCs. T cells, especially CD8 þ T cells, migrate into all layers of the epidermis in psoriasis lesions. CD11c þ DCs also infiltrate the epidermis of psoriasis lesions, but they are confined to the lower cell layers of the epidermis. Langerhans cells continue to be present in psoriatic epidermis, but they appear to migrate into the upper spinous zone, in contrast to normal skin where the distribution is relatively uniform. Neutrophils accumulate in small aggregates in the cornified epidermis.
T cells are thought to be critical pathogenic triggers in psoriasis where epidermal CD8 þ and dermal CD4 þ T cells are highly activated and express CD25 (the interleukin (IL-2) receptor a-subunit). 17 Both of these T-cell subsets have type-1 effector functions and can be classified as T c 1 and T h 1 populations, respectively. 18 TNF and IFN-g, are synthesized by these activated T cells and are key cytokines for activating keratinocytes. More than 100 genes are induced by short-term exposure of keratinocytes to these cytokines. 15, 16 The CD8 þ subset of T cells that diffusely infiltrate the epidermis of psoriasis lesions are mainly LFA1 hi CD8 þ T cells. Most T cells in psoriasis lesions are memory cells (CD45Ro þ or CD45RAÀ) 19, 20 and many specialized subsets are represented in this infiltrate. A significant fraction of T cells in lesions express the epithelial homing integrin a E b 7 . 21 They also express the chemokine receptor CXCR3, which allows them to migrate towards CXCL9/ MIG, CXCL10/IP-10 and CXCL11/I-TAC. These chemokines are synthesized at increased levels by keratinocytes in psoriasis lesions. Although the pathogenic action of CD8 þ (T c 1) T cells in psoriasis lesions may be mostly related to cytokine secretion and migration through the epidermis, they also synthesize the cytotoxic granule components Tia-1, granzyme B and perforin. 22, 23 Normal skin, as well as non-lesional skin of psoriasis patients, contains resident populations of immature DCs in the epidermis and dermis. However, psoriasis lesions contain several alterations in DCs. First, there is a marked increase in the number of myeloid DCs, marked by the integrin CD11c, in the dermis. Moreover, CD11c þ DCs may be the largest subset of infiltrating leukocytes in psoriasis lesions. 24 CD11c þ DCs express high levels of TNF and have strongly upregulated expression of inducible nitric oxide synthase (iNOS), an enzyme which synthesizes nitric oxide. Hence this group of myeloid DCs may be the human equivalent of TNF and iNOSproducing DCs (TIP-DCs), a newly discovered DC subset with direct inflammatory/effector functions. 25 Whereas myeloid DCs are confined to the dermis in normal skin, TIP-DCs invade into the epidermis in psoriasis lesions. Myeloid DCs may trigger epidermal hyperplasia directly by secretion of IL-20, a cytokine that not only stimulates keratinocyte proliferation, but which also induces key inflammatory gene products in keratinocytes. 26 Second, DCs in psoriasis lesions have more capacity to stimulate T-cell proliferation compared to DCs in normal skin. 27 This increased stimulatory activity correlates with upregulation of HLA-DR, CD40, CD86 and other surface molecules which are expressed at higher levels on mature or activated DCs. Markers of mature DCs, including DC-LAMP and CD83, are expressed on many DCs in psoriasis lesions, whereas very few DCs in normal skin have these markers. Activated myeloid DCs may also produce IL-23; 28 this is a potent T-cell activating cytokine that is discussed further below. Mature DCs form aggregates or clusters with T cells in the dermis of psoriasis lesions. These mixed aggregates, which consist of many hundreds of cells, may perpetuate T-cell activation in psoriasis lesions, and conversely, products of activated T cells (secreted cytokines or induced surface molecules such as CD40L) may react with DCs in these regions to induce/sustain mature populations of DCs. Chemokines that organize lymphoid structures in lymph nodes are, surprisingly, highly upregulated in psoriatic skin lesions and may thus create secondary lymphoid structures in the skin. A third feature of DCs in psoriasis lesions is the marked accumulation of plasmacytoid (CD11cÀCD123 þ ) DCs. 29 This group of DCs, which secrete high levels of IFN-a upon activation, have been proposed as a critical early initiator of cellular inflammation in the formation of psoriasis lesions.
Two other types of T cells may also be important in psoriasis: IL-17 producing cells and natural killer (NK)-T cells. In mice, IL-23 induces IL-17-producing T-cells which are effectors distinct from T h 1 cells. 30 Many CD4 þ and CD8 þ T-cell clones isolated from psoriasis lesions produce IL-17.
31 IL-23 is produced at elevated levels in psoriasis lesions, 28 so it might serve as a stimulus for in situ differentiation of IL-17 þ effectors. IL-17 has been shown to synergize with TNF and IFN-g for induction of IL-6, IL-8 and other inflammatory products in keratinocytes. 31 Excessive transcription of genes that lead to DC activation or those that restrict the migration of mature DCs from peripheral tissues may be central to sustaining T-cell activation. Alternatively, some psoriasis suscepti-bility genes may affect deletion of self-reactive T cells, the induction of regulatory T cells by changing signal transduction through the T-cell receptor (TCR) or costimulatory pathways, may trigger an inappropriate innate immune response or may alter the threshold for immune cell activation or the rate of immune synapse formation/dissolution. 32 Previously, we proposed a relatively simple 'Type-1' pathway in psoriasis that links expression of IL-23 to activation of Type-1 T cells (and potentially IL-17 þ T cells), with downstream activation/amplification of inflammation through a group of IFN-induced gene products that constitute B5% of the psoriasis transcriptome. 33 In this model, TNF, IFN and IL-17 are all likely to be important T-cell derived cytokines that stimulate these 'Type-1' pathway genes. Endstage products of the Type-1 pathway include a number of chemokines that probably stimulate on-going leukocyte recruitment into skin lesions on a chronic basis. Figure 2 Network model of inflammatory pathways commonly upregulated in psoriasis. Ingenuity Pathways Analysis (Ingenuity Systems, www.ingenuity.com) was used to identify relevant biological networks. Shaded nodes represent upregulated genes in psoriasis identified by microarray analysis or genes thought to be primary biological triggers (e.g. TNF, IFNG). The meanings of node shape are indicated. Solid lines imply direct relationships between proteins; dotted lines imply indirect interactions. Relationships are primarily due to co-expression, but can also include phosphorylation/dephosphorylation, proteolysis, activation/deactivation, transcription, binding, inhibition, biochemical modification.
The 'Type-1' pathway model is probably a gross oversimplification of complex interactions of inflammatory molecules in psoriasis lesions, especially as 4100 inflammatory gene products are upregulated in psoriasis lesions. It is likely that products of genes which are upregulated in psoriasis interact in complex circuits to regulate activation of skin-resident cells, infiltrating leukocytes and inflammatory pathways. One example of interacting pathways is shown in Figure 2 . This pathway, although shown as interacting genomic elements, links activation or accumulation of several cell types in psoriasis lesions. For example, the chemokines CCL20/MIP-3a, CCL19/MIP-3b, CCL21/6Ckine and CXCL12/SDF-1 are key attractors of DCs that we have termed TIP-DCs (see above). 4, 32, 33 In addition, cytokines like IL-12 and IL-23 that stimulate T h 1 T-cells (defined by expression of g-IFN or the IFNG gene) and/or T h 17 Tcells (defined by expression of IL-17 gene/cytokine) are produced by DCs in psoriasis lesions. 28 Note upregulation of the IL-23R, which may indicate increased sensitivity to IL-23 cytokine production in psoriasis. Disease-relevant T cells may be drawn into skin lesions through increased expression of chemokines like CCL27/CTACK, CXCL9/MIG, CXCL10/IP-10, CXCL11/I-TAC and several other chemokines that are expressed in this network. Neutrophils may be attracted into skin lesions by the chemokines IL-8 and CXCL1/ Gro-a. 4, 32, 33 At least three products of this network, IL-1A/IL-1a, TGFA/TGF-a and IL-19 can serve as keratinocyte mitogens, whereas the cytokines IFNG, TNF and IL-17 act on keratinocytes as inducers of chemokines, as well as many other genes that become upregulated in psoriasis, including defensin genes (DEFB4 and DEFB103A genes).
34 STAT1, shown in the network, is among the most upregulated transcription factors in psoriasis and may account for a very high fraction of upregulated gene products. 33 Therapeutics which reverse psoriasis in a considerable fraction of treated patients (infliximab, etanercept, adalimumab and CNTO-1275) target key cytokines that drive expression of key elements of this network. 35, 36 Uninvolved skin of patients Background skin of psoriasis patients is very similar to normal skin until a psoriasis lesion is triggered. The earliest recognizable change in eruptive lesions is the accumulation of mononuclear leukocytes (T cells and monocytes/DCs) around dermal blood vessels, without any epidermal reaction. 37 It is not known what triggers these cell accumulations but it could be in response to some antigen-based trigger, or to a different innate stimulation, leading to upregulation of chemokines and adhesion molecules.
Very little molecular information is available about this stage of disease evolution. However, background (nonlesional) skin of psoriasis patients undergoing a psoriatic 'flare' contains more T cells than found in skin of normal controls. Several inflammatory genes (CD4, CD103/aEintegrin, CD11c and BRAK/CXCL14) are expressed at higher levels compared to normal skin. 4 CXCL14 is a monocyte-selective chemokine, which may explain increased expression of CD11c (selectively expressed by myeloid cells). 38 
Genetics of psoriasis
At this point, complex gene expression changes in psoriasis are well described, but functional relationships between the predisposing genetic factors and the cellular elements of pathogenic immunity are not well worked out. It is expected that knowledge of predisposing variants in susceptible individuals and exposure to environmental triggers will eventually explain the numerous changes that exist in psoriatic skin. What is becoming apparent is that a number of susceptibility factors in the population lead to subtle alterations in activity of components of the immune system. Psoriasis susceptibility locus 4 (PSORS4) in the EDC on chromosome 1, for instance, may specifically alter keratinocyte differentiation, but involvement of other loci remains unclear.
The existence of a genetic contribution of psoriasis is well accepted. Previous twin studies in psoriasis report that concordance of the disease in monozygotic twins is much higher than in dizygotic twins, being approximately 72 and 15-23%, respectively, for northern European individuals. A similar trend is also observed in Australian individuals. These results indicate that genetic components play a role in predisposition to the disease, and it is estimated that the heritability for psoriasis is between 60 and 90%. 39 Currently, few genes for psoriasis have been conclusively identified, although genome wide linkage scans have revealed 20 potential loci over the past 12 years. 40 As with all complex diseases, linkages and associations with psoriasis have not always been replicated in other cohorts. This can be due to low effect size of individual genetic variation, ascertainment bias, geneenvironment interactions and other confounding factors. Among the reported psoriasis susceptible loci, the locus in the major histocompatibility complex (MHC) on chromosome 6p21, known as PSORS1, is the only one that has been consistently identified in genome-wide scans, accounting for one-third to one-half of the genetic liability to psoriasis.
PSORS1
The strong association of HLA-Cw6 allele in this locus with psoriasis was first reported in the Finnish population over 26 years ago. 41 However, the exact location of PSORS1 gene remains controversial owing to extensive linkage disequilibrium across this region. Two genes lying within this interval have been intensively studied with respect to their role in psoriasis susceptibility. One is HCR (helix coiled coil rod homolog); 42 the other is corneodesmosin (CDSN/S). CDSN is expressed in terminally differentiated keratinocytes and in the inner root sheath of hair follicles. [43] [44] [45] It localizes to the modified desmosomes of keratinocytes in the stratum granulosum and stratum corneum. The serine and glycine-rich terminal domains of CDSN that are essential for cell adhesion are sequentially cleaved during skin desquamation. 46, 47 Apart from the skin, CDSN mRNA is only detected significantly in the placenta and in the thymus. 48 Several recent studies inducate that PSORS1 is likely to lie very close to HLA-C, and distinct from the region harboring CDSN and HCR. Two single-nucleotide polymorphisms (SNPs) (SNP n.9 and SNP n.7), lying B5.7
and B10 kb, respectively upstream from the start site of HLA-C exhibit stronger association with psoriasis than any other SNP in the region. 49 A study from our group looking at both SNPs and classical HLA alleles revealed that haplotypes harboring HLACw*0602 and HLACw*1203 were over-transmitted to affecteds, suggesting that a variant or combination of variants exclusive to these haplotypes were predisposing. 50 Interestingly, one of these variants leads to acquisition of an additional site for the transcription factor RUNX, within intron 7. This is highly correlated with the SNP n.9 and SNP n.7 polymorphisms (r 2 ¼ 1). A recent study comparing risk haplotypes from unrelated individuals as well as families with earlyonset psoriasis revealed that HLA-Cw6 may be 'the' risk allele for psoriasis in this locus. 51 Given the confounding discrepancies in results from different groups and the importance of the identification of PSORS1, a psoriasis consortium has been established to investigate PSORS1 across a combined set of patient/family cohorts. This exploits knowledge from the HapMap project that has facilitated the identification of tagging SNPS and haplotypes across the region. 52 Although PSORS1 is the only locus for psoriasis identified in all genetic studies to-date, its estimated penetrance is less than 15%, indicating that other genetic/environmental factors may also contribute to the liability of the disease. The known remaining potential loci are discussed below. Some may confer effects independent of PSORS1, others may be PSORS1 modifiers.
It is also worth noting, that HLA class I alleles rarely show evidence for linkage to psoriasis in large multiply affected families. There are two possible explanations for this. Some large families may harbor other loci, and be truly PSORS1 negative (e.g. a locus on chromosome 18p identified with linkage analyses in the Finnish population). 53 In other large families, multiple affected may harbor HLA-Cw*0602 on multiple haplotypes. 50 PSORS2 PSORS2 on chromosome 17q25 was the first identified non-MHC locus that confers susceptibility to psoriasis. Our group initially identified this region by genomewide linkage scan on eight Caucasian affected families, among which PS1 family (19 affected and 12 unaffected members) showed strong linkage to D17S784 marker with a maximal two point logarithm of the odds (LOD) score of 5.33, with high penetrance. 54 Evidence from a recent linkage study on a single large-pedigree in Taiwan replicated our linkage findings, mapping this psoriasis susceptibility locus to the distal end of chromosome 17q. 55, 56 In this case, a LOD score of 7.67 at y ¼ 0.01 was obtained with D17S784, and as with the former study, no recombinants were detected with the most distal locus, D17S928 that lies B800 kb from the 17q terminus. A third independent PSORS2-linked Israeli Jewish Moroccan family was also recently identified. 57 The disease in this family was also linked to D17S928 (maximum multipoint LOD score of 8.79 at y ¼ 0) and segregates with a frameshift mutation in ZNF750 (FLJ13841), which encodes a putative C2H2 zinc-finger protein. The general applicability of this allelic effect of ZNF750 to poriasis susceptibility is not clear at this point. It is conceivable that the family studied was somehow unique in its presentation of psoriasis. For example, clinical manifestations included not only both plaque psoriasis and erythrodermic psoriasis, but also very mild skin lesions and histopathologic findings reminiscent of pityriasis rubra pilaris. What may be noteworthy is that ZNF750 is normally expressed in keratinocytes but not in fibroblasts and is hardly detectable in CDA lymphocytes.
Proximal PSORS2 locus A five-marker variant in a region on chromosome 17q25 harboring SLC9A3R1 and NAT9 was identified with association mapping. 58 Both genes encode proteins that play a role in negatively regulating immune cell activation. This role seems to be more pronounced when the non-psoriasis-associated allele is present. One psoriasis-associated allele from this five marker haplotype leads to loss of a putative site for the RUNX family of transcription factors. This is of interest as RUNX1 and RUNX3 play a major role in hematopoietic development and thymic selection (see below). Moreover, alterations of RUNX binding sites have also been reported as susceptiblity variants for systemic lupus erythematosus and rheumatoid arthritis. 59, 60 In all cases these variants lie in intronic or in intragenic regions. It is currently not clear if it is RUNX1, RUNX2 or RUNX3 that is binding to the altered sites in auto-immune diseases, as all have been reported to recognize the same consensus sequence TGt/cGGT. RUNX proteins are key regulators of lineagespecific gene expression. RUNX1 is a master-regulator of the hematopoietic system. RUNX2 is required for osteogenesis and RUNX3 controls neurogenesis.
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RUNX1 is also frequently disrupted in acute myelocytic leukemia via translocation or point mutation. 62 A RUNX3 knockout mouse has been described with eosinophilic airway inflammation. 63 They also spontaneously develop an inflammatory bowel disease that is characterized by leukocyte infiltration, mucosal hyperplasia, formation of lymphoid clusters and increased production of immunoglobulin A.
64 RUNX3-deficient cytotoxic T cells, but not helper T cells, have defective response to antigen. The epidermis of RUNX3 knockout mice also lacks epidermal Langerhans cells but not dendritic epidermal cells. RUNX3 also plays a role in development of gamma delta T cells (found in skin). It is detected mainly in the CD4ÀCD8 þ subset of thymocytes, and may play a role in the development and maturation of these cells. 65 These findings provide important evidence for a role for RUNX3 pathways in tolerance or inflammation. From the perspective of complex autoimmune diseases it suggests that the altered RUNX sites (generally polymorphisms) in different genes encoded by specific inflammatory cells or in cells of target tissues may increase the risk of autoimmune disease by altering their normal regulation (e.g. lowering the threshold for activation of immune genes).
RAPTOR
A second more distal locus mapping distal to D17S784 and within the region of linkage seen in the three large families described above harbors RAPTOR (Regulatory associated protein of mTOR). Intronic SNPs have been shown to be associated with psoriasis in our set of US families and an independent set of families from the UK. 58, 66 The significance of this association is currently not understood.
Variants other than those from PSORS1 and reported to be associated with psoriasis in at least one study are described in Table 1 . PSORS3 SLC12A8, (solute carrier family 12 (bumetanide-sensitive Na-K-Cl cotransporters), member 8) was the first gene proposed to be associated with psoriasis susceptibility. 67 This gene is a member of the cation-chloride-coupled cotransporter gene family, 68 although the substances it transports are unknown. A five-marker haplotype from the 3 0 end of the SLC12A8 gene was associated with psoriasis in Swedish families, in keeping with the fact that some susceptibility variants of complex traits affect gene regulation rather than changing coding sequence. Association of SLC12A8 and psoriasis has not been replicated in other populations until recently when examination of SNPs and haplotypes in a set of cases/ controls and trios from Germany found association in the cases/controls, but not trios. 69 Association in cases but not trios in general creates concern about underlying population stratification in the case/control population.
PSORS4: the EDC on chromosome 1q21
This harbors a number of genes involved in epidermal differentiation. They form a cluster of genes on chromosome 1q21 and span over 2 Mb. Linkage to chromosome 1q21 was first described in Italian families, 70 although suggestive evidence for linkage was seen at the same time in our cohort of multiplex families from the US, and was replicated in our cohort of affected sibship pairs. 71 Recent unpublished results suggest that PSORS4 lies within a region harboring SPRR and LEP genes. Hence, PSORS4 is likely to be involved in terminal differentiation of keratinocytes. There is also evidence for interaction between PSORS1 and PSORS4.
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PSORS4 is one of four loci also shown to be linked to atopic dermatitis (1q21, 3q21, 17q25 and 20p) . 73 These findings implicate the same genetic defects, potentially keratinocyte derived, in both diseases. However, in several recently described studies, the defects have been shown to be different. For example, two loss-of-function mutations (R501X and 2282derl4) in the filaggrin gene that cause ichthyosis vulgaris, one of the most common inherited skin disorders of keratinization, have been reported to be strong predisposing factors for AD in the heterozygous state. These mutations are found in B9% of Europeans, yet in 44-76% of cases. 74 In the case of chromosome 17q25, associations between the SLC9A3R1/ NAT9 psoriasis-associated variants, are not seen in atopic dermatitis.
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PSORS9
Chromosome 4q28-q31 has continued to be of interest with respect to psoriasis because although the effects of this locus are relatively weak, it is detected consistently in many genome-wide scans of families from both Europe and the Han Chinese population. 76 This suggests that the susceptibility variant arose before the divergence of these two populations (B70 000 years ago). An alternative explanation is that the variant has arisen independently in the two populations. Different genetic analyses point to the existence of several susceptibility genes in this region of the genome, and chromosome 4q may harbor several loci for psoriasis susceptibility. This region harbors over 300 genes, but there are some compelling candidate genes including IL-15, and IFN regulatory factor 2 (IRF-2). The latter is an important candidate as it is involved in negative regulation of IFN-g signaling. Moreover, mice deficient in IRF-2 display psoriasis-like skin abnormalities. Weak association of IRF-2 variants with psoriasis has been reported (PSORS3). 77 It is not clear if this is because the true variant has not been detected in this, or a nearby gene, or if the association is spurious. Abbreviations: IL, interleukin; mTOR, mammalian target of rapamycin; RAPTOR, regulatory associated protein of mTOR; SNP, singlenucleotide polymorphism; TNF, tumor necrosis factor; UTR, untranslated region.
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Recently, a psoriasis patient with a balanced translocation involving chromosome 4q was reported. This disrupts the MGST2 (microsomal glutathione S-transferase 2) gene which is involved in catalyzing the conjugation of leukotriene C4 (LTC4), and the conversion of LTA4 into LTC4. 55 It is hypothesized that the elevated level of LTB4, found in psoriatic lesions could be due to an accumulation of LTA4. We examined association of MGST2 tag SNPs with psoriasis and did find some evidence for association (P ¼ 0.004) with an intronic SNP rs2602238 (Helms and Bowcock, unpublished results) . This suggests that MGST2 could be a risk factor for this disease. Interestingly a novel non-synonymous mutation in MGST2 has been seen in one Chinese family with psoriasis, 78 however, no association with MGST2 SNPs was seen in an independent study investigating a cohort of Chinese patients. 79 Overlap of psoriasis loci with other auto-immune and inflammatory diseases Psoriasis is an 'inflammatory' disease that strongly depends on activation of the cellular immune system. It is not known if it is officially an autoimmune disease with reactivity to self-antigens. Neverless, there is overlap with a number of other 'autoimmune' human diseases like inflammatory bowel disease, Crohns, diabetes and multiple sclerosis. This overlap is seen both at the level of altered biochemical pathways, and with respect to the locations of loci mapped by linkage analysis. 73, 80 Genes that have been shown to be shared nearly always encode products that regulate immune system activation. They are described below:
PTPN22 (protein tyrosine phosphatase, non-receptor type 22) is expressed primarily in lymphoid tissues. The R620W alteration of PTPN22 is associated with type-I diabetes, RA and SLE. [81] [82] [83] When arginine is present, it is hypothesized that the protein can bind Csk and hence, prevent spontaneous T-cell activation by dephosphorylation. When the autoimmune-associated tryptophan allele is present, PTPN22 can no longer bind Csk, and hence, a critical regulatory element of immune cell activation cannot be employed. Several studies including our own have not revealed association of psoriasis with PTPN22 SNPs. However, in one study from Germany, although association with 620W and psoriasis was not detected, significant association with one haplotype of the LD block encompassing PTPN22 as well with another haplotype within an adjacent telomeric LD block was detected. 84 This suggests that other variants of PTPN22 may be associated with psoriasis.
SUMO4: An M55V change within SUMO4, that encodes a small ubiquitin-like modifier 4 protein has been shown to be associated with type-I diabetes.
85
SUMO4 binds I kappaB a and negatively regulates nuclear factor kappaB (NF-kB) transcriptional activity. The M55 V substitution resulted in 5.5 times greater NFkB transcriptional activity and approximately 2 times greater expression of IL-12B, an NF-kB-dependent gene. We examined association of this alteration with psoriasis using family-based methods and obtained a P-value of 0.05, suggestive of association (Helms and Bowcock, unpublished results). The Rel/NF-kB transcription factors play a central role in numerous cellular processes, including the stress response and keratinocyte proliferation and differentiation. This is in agreement with recent observations that activation of NF-kB plays a significant role in the pathogenesis of psoriasis where basal level of constitutive active phosphorylated NF-kB/RelA is detected in uninvolved epidermis from psoriasis patients, in contrast to normal epidermis where active nuclear NFkB is not detected. Active phosphorylated NF-kB/RelA is also upregulated in the epidermis from psoriatic plaque. 86 Hence, a role for SUMO4 in psoriasis is plausible.
TNF-a: Many lines of evidence point to an important role for TNF in psoriasis, and many genes upregulated in involved skin, are regulated, at least in part, by this cytokine (see above). TNF increases the synthesis of proinflammatory cytokines and leads to the activation of multiple signaling pathways, including NF-kB. Polymorphisms in the promoter of TNF, regulating its level, have been of interest for many years and some evidence has been provided for association with psoriasis. 87, 88 However, the gene encoding TNF-a lies in the MHC region, and exhibits association with HLA class I alleles such as HLA-C. Hence, associations with TNF-a polymorphisms with psoriasis could be due to its proximity with HLA-C. The existence of an independent effect of TNF-a variants in psoriasis susceptibility or severity, independent of HLA-C need to be formally investigated.
IL-12B/IL-23R: Two studies have considered IL-12B as a candidate psoriasis gene. One excluded association with a promoter polymorphism. 89 The second identified a polymorphism in the 3 0 UTR (1188A/C) that was associated with psoriasis. In this case, A was more common in cases. 90 More recently, a global association scan indicated that variants lying 60 kb upstream of the mRNA start site or in the 3 0 regulatory region of IL-12B are associated with psoriasis. 91 Two missense changes within a receptor subunit (IL-23R), were also reported to be associated with disease. This is interesting for a number of reasons. IL-12 plays a key role in regulating both innate and adaptive immunity. It is a heterodimeric molecule comprised of a subunit encoded by IL-12B (p40) and a p35 subunit, which together form a p70 molecule. This binds to a high affinity receptor, IL-12R. IL-12 is produced early on during infections or the inflammatory response by DCs and activated macrophages. 92 It acts together with IL-2 and TNF-a to induce IFN-g expression in NK cells and acts on both CD8 þ T cells and NK cells to enhance their toxicity. IL-12 also suppresses ultraviolet-mediated apoptosis of keratinocytes by inducing DNA repair. 93 IL-23 is an IL-12 cytokine family member that shares the p40 subunit with IL-12. IL-23 has been proposed to be the main cytokine stimulating a new lineage of effector CD4 þ T cells called T h 17 cells. 94 These are distinct developmentally and functionally from classical T h 1 and T h 2 lineages and are characterized by production of IL-17. Like T h 1 and T h 2, T h 17 cells are proposed to have evolved to provide adaptive immunity tailored to specific classes of pathogens, such as extracellular bacteria. Aberrant T h 17 responses have also been implicated in a growing list of autoimmune disorders. 95 A change in IL-23R that led to less receptor function, would be expected to skew T-cell development in the direction of the T h 1 class of T cells, which is clearly activated in psoriasis lesions.
Interleukin cluster on chromosome 1q31-q32: This harbors a 200 kb region containing genes for IL-10, MDA7, IL-19 and IL-20. Association with genes in this region has been investigated. Some evidence for association with psoriasis and a haplotype harboring IL-19 and IL-20 genes has been provided, 96 albeit with modest P-values. A polymorphic microsatellite in the IL-10 promoter also revealed evidence for association with psoriasis in patients with a family history of disease. 97 Protective effects conferred by some alleles and haplotypes within this cluster of genes has also been proposed, along with suggestions that some alleles influence severity or clinical course of disease. 98, 99 A comprehensive association analysis of alleles and haplotypes within this cluster of genes is warranted in other patient populations.
Conclusion
Existing evidence supports the concept of psoriasis as a chronic inflammatory skin disorder, mediated by T cells, DCs and inflammatory cytokines. The availability of methods to analyze tissue and large-scale genomic data allow the identification of many cellular and gene expression alterations in psoriatic lesions. A number of chromosome regions that could harbor potential susceptibility loci to psoriasis are also being identified via largescale linkage and association studies. However, as with all complex disorders, these loci are not always been replicated in other pedigrees or cohorts, which can be due to multiple confounding factors commonly seen in genetic study of complex disorders. Moreover, the correlation between genetic predispositions and the changes of cellular elements in psoriasis are still unclear at this point. Therefore, future research will focus on integrating the knowledge of genetic variations into the picture of molecular and cellular mechanisms of psoriasis, which will in turn facilitates the discovery of novel therapeutic targets and the development of strategies for individualized medicine.
